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One-Pot Synthesis of pH-Responsive Eudragit-Mesoporous
Silica Nanocomposites Enable Colonic Delivery of
Glucocorticoids for the Treatment of Inflammatory Bowel
Disease
Zhi Qu, Kuan Yau Wong, Md. Moniruzzaman, Jakob Begun, Hélder A Santos,
Sumaira Z. Hasnain, Tushar Kumeria, Michael A. McGuckin, and Amirali Popat*
Oral glucocorticoids are backbones for the acute management of
inflammatory bowel disease (IBD). However, the clinical effectiveness of
conventional oral dosage forms of glucocorticoids is hindered by their low
delivery efficiency and systemic side effects. To overcome this problem, a
smart drug delivery system with high loading capacity and colonic release by
coating functionalized mesoporous silica nanoparticles (MSNs) with a
pH-responsive polymer Eudragit S100 is proposed. In vitro dissolution tests
show that Eudragit-coated MSNs can limit the burst release of loaded
prednisolone and budesonide in the gastric environment with more than 60%
of the drugs released only at colonic pH (i.e., pH ≥ 7). In vivo therapeutic
efficacy of budesonide-loaded nanoparticles is tested in a murine model of
dextran sodium sulfate-induced colitis. An oral budesonide dose of
0.2 mg kg−1 nanoparticles with Eudragit coating improves the disease activity
index compared to other groups. Interestingly, both coated and uncoated
nanoparticles show pathological improvements demonstrated by similar
levels of histological colitis score. However, coated nanoparticles significantly
decrease mRNA expression of the cytokines (Il-1𝜷, Il-17, and Il-10) particularly
in proximal colon, indicating colonic delivery. Overall, this study
demonstrates the effectiveness of a simple method to fabricate targeted
nanomedicine for the treatment of IBD.
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1. Introduction
Inflammatory bowel diseases (IBD) are a
group of chronic inflammatory conditions
of the intestinal tract.[1] Ulcerative colitis
(UC) and Crohn’s disease (CD) are the
two main forms. IBD affect more than
7 million people across the world, with
an annual economic burden of 15 billion
USD.[2] Although a range of genetic, im-
munological, and environmental factors are
known to play a role in the development
of IBD, the causes of IBD are not yet
fully understood.[3] Currently, there is no
cure for IBD, and management strategies
have focused on inducing and maintaining
remission. IBD management typically in-
cludes use of amino salicylates, antibiotics,
corticosteroids, immunomodulators, and
biologics.[4] Corticosteroids are commonly
prescribed for acute IBD; however, current
corticosteroid medications still result in un-
desirable systemic side-effects because of
the absorption along upper gastrointestinal
tract (GIT).[5] Glucocorticoid treatment for
IBD is well-known to lead to bone density
loss, hyperglycemia, glaucoma, cataracts, skin thinning, im-
paired growth, adrenal suppression, and steroid dependency.[6]
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Despite their well-known side-effects, corticosteroids are still
used frequently for the treatment of IBD due to their rapid onset
of action and effectiveness at inducing remission, compared to
other therapeutics, such as immunomodulators and biologics.[7]
A potential alternative to oral glucocorticoid delivery is offered by
direct rectal therapy, which provides localized treatment for man-
agement of IBD in the distal colon.[8] However, rectal adminis-
tration has poor patient compliance and is not effective for more
proximal disease in the colon and small intestine.[9] Considering
thatmost IBDpatients require lifelong diseasemanagement, oral
delivery promises the highest patient compliance and adherence.
The ideal oral drug delivery system for IBD should enable se-
lective and exclusive delivery of drug to the inflamed sites to
achieve maximum therapeutic efficacy and limited side-effects.
Current strategies include use of prodrugs, such as sulfasalazine,
which is activated by bacterial mediated reduction in the dis-
tal colon,[10] and coatings of non-starch polysaccharide (COLAL-
PRED, Budenofalk, and Entocort[11]). Obstacles, such as inabil-
ity to target loaded drug to the diseased tissue, incomplete tablet
disintegration, high risk of systemic drug exposure, and high
cost associated with injectable biologics are still limiting better
management of IBD.[5a,12] Although these strategies provide im-
proved performance, these formulations do not perfectly over-
come the above challenges for targeting the inflamed regions in
the colon, while avoiding systemic exposure. Hence, new drug
delivery technologies for colon targeting are urgently required.
The pH-responsive nanomedicines have been widely used for
targeting intracellular compartments in tumors and inflamed
tissues.[13] They have distinct advantages for colonic delivery be-
cause their properties of drug release at specific pH fit well with
the physiological environments of the GIT.[14] Polymers have
been extensively investigated for several decades and many pH-
responsive polymers have been applied to produce biocompatible
nanocarriers.[15] Eudragit S100 polymers are among one of the
most studied pH-responsive polymers for oral delivery of small
molecules. Eudragit S100 is a commercialized pH-sensitive acry-
late for enteric coating for tablets and capsules.[16] It has a disso-
ciation pH above 7, which is suitable for colonic delivery. How-
ever, conventional pH-responsive formulations, such as pellets,
capsules, and tablets, can be subjected to rapid clearance due to
diarrhea, a characteristic of IBD. Diarrhea can lead to decreased
GIT residence time and result in incomplete tablet disintegra-
tion and rapid excretion, which complicates dosing and impairs
therapeutic outcomes.[17]
In this regard, nanoparticles for drug delivery have recently at-
tracted tremendous attention because of their unique ability to
passively target the inflamed colon providing local release.[17,18]
Moreover, disrupted intestinal barrier at inflamed epithelium
provide entrapped particles access from intestinal lumen to the
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inflamed colonic tissues.[19] Previous studies have found that
enhanced therapeutic efficacy can be achieved by utilizing the
inflammation-selective adhesion property of nanoparticles in ex-
perimental colitis.[20] Based on this, more and more newly de-
signed nanoparticle-based drug delivery systems, such as lipo-
somes, polymers, hydrogels, and inorganic nanoparticles, are
developed achieve colon targeted delivery by combining pH-
responsive release strategy.[21] However, many of these nanopar-
ticles have poor encapsulation efficiency, suffers from burst re-
lease, require costly and complex manufacturing methods.[22]
Mesoporous silica nanoparticles have been studied as drug de-
livery systems for more than a decade.[23] Advantages include
their biocompatibility, high surface area (>1000 m2 g−1), tun-
able pore sizes, uniform particle size, large pore volumes, ease
of functionalization, and flexibility in loading drugs of differ-
ent physicochemical properties.[24] The large surface area of
mesoporous silica nanoparticles provides rapid adsorption of
drug molecules by capillary force.[25] Orally administered silica
nanoparticles can be easily excreted or degraded into silicic acid,
which is the most bioavailable form of silicon.[26] Another advan-
tage of mesoporous silica nanoparticles is their large loading ca-
pacity due to high surface area and large pore volumes.Moreover,
numerous of silanol groups on the surface of silica nanoparticles
provide perfect binding sites for functional ligands and chemical
groups to fulfill specific requirements. Coating of silica nanopar-
ticles can provide drug release based on stimuli, and thus, pro-
vide better control of drug release.[22a,27]
Here in, we have developed a one-step rotary-evaporation
method for in situ drug loading and pH-responsive coating. Uni-
form coating and high loading amounts for glucocorticoids, pred-
nisolone, and budesonide were achieved by this method in one-
step. In vitro release studies showed that after coating, the loaded
drug was mostly released above pH 7 for both glucocorticoids.
Budesonide was selected for further in vivo efficacy study of
drug-loaded particles on a dextran sodium sulfate (DSS) murine
model since in our in-house testing prednisolone did not reverse
DSS-induced inflammation in mice.[28] Histological assessment
of colonic tissues showed that the nanoparticle-encapsulated
budesonide significantly reduced inflammation compared to free
budesonide. At biochemical levels, the mRNA expression of cy-
tokine Tnf-𝛼 and interleukins (IL)-1𝛽, Il-10, and Il-17 of pro-
inflammatory and anti-inflammatory cytokines indicate signifi-
cantly greater reduction in the pro-inflammatory cytokine levels
in the case of Eudragit S100 coated particles, confirming our hy-
pothesis.
2. Results and Discussion
2.1. Characterization of Mesoporous Silica Nanocomposites
Schematic describing our one-pot pH-responsive mesoporous
silica nanoparticles is shown in Scheme S1, Supporting Infor-
mation. The prepared MSNs were systematically characterized.
Particle size and morphology were confirmed with transmis-
sion electron microscopy (TEM) (Figure 1). Pristine MSNs ap-
pear around 100 nm in diameter, spherical in shape with slightly
rough surface and a hexagonal pore arrangement. Amino-
modified particles (MSN-A) show unchanged morphology and
pore arrangement, confirming no pronounced change on shape
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Figure 1. TEM images of pristine (MSN), amino-modified (MSN-A) and
Eudragit S100 coated particles (MSN-A-Eu). Scale bars are 200 nm (left
column) and 50 nm (right column).
Table 1.DLS particle size, surface charge and polydispersity index (PDI) of




PDI Surface charge [mV]
MSN 110.3 ± 4.3 0.16 ± 0.01 −13.5 ± 1.0
MSN-A 143.4 ± 3.7 0.11 ± 0.01 +33.6 ± 1.1
MSN-A-Pre 160.1 ± 14.6 0.21 ± 0.04 +30.2 ± 2.0
MSN-A-Bud 168.5 ± 10.8 0.26 ± 0.08 +29.8 ± 2.5
MSN-A-Eu 224.6 ± 15.0 0.41 ± 0.10 −20.9 ± 1.4
MSN-A-Eu-Pre 238.3 ± 12.7 0.42 ± 0.11 −19.2 ± 2.8
MSN-A-Eu-Bud 241.7 ± 18.6 0.45 ± 0.16 −19.5 ± 3.5
or the hexagonal structure after modification.[29] For coated par-
ticles, a layer of Eudragit S100 can be observed coated over the
particles.
Particle size was measured by dynamic light scattering (DLS).
Pristine MSNs show a hydrodynamic diameter of ≈110 nm,
which increased to ≈143 nm for MSN-A (Table 1). Drug-loaded
particles show slightly larger diameter (≈160 nm for MSN-A-Pre
and ≈168 nm for MSN-A-Bud), which could be a result of in-
creased hydrophobicity from drug loading on the porous surface
of the nanoparticles. Hydrodynamic diameter further increases
to≈225 nm (MSN-A-Eu) after coating. Coated particles with drug
Table 2. Surface area and porosity of synthetized MSNs. Data represent






MSN 5 0 ± 30 1.1 ± 0.02 2.1 ± 0.02
MSN-A 4 9 ± 15 1.0 ± 0.03 2.0 ± 0.01
MSN-A-Pre 2 1 ± 7 0.5 ± 0.02 N/A
MSN-A-Bud 3 5 ± 11 0.7 ± 0.02 N/A
MSN-A-Eu 2 4 ± 14 0.5 ± 0.01 N/A
MSN-A-Pre-Eu 2 6 ± 12 0.4 ± 0.02 N/A
MSN-A-Bud-Eu 2 0 ± 14 0.5 ± 0.02 N/A
show the size of ≈238 nm (MSN-A-Pre-Eu) and ≈242 nm (MSN-
A-Bud-Eu). Zeta-potential of synthetized MSNs was measured in
pH 5.5 universal buffer to confirm amino group modification
and Eudragit S100 coating. The pristine particles show a negative
zeta-potential of −13.5 mV, which is reversed to +33.6 mV be-
cause of amino groups after modification. Particles show slightly
lower zeta-potential after drug loading (+30.2 mV for MSN-A-
Pre and +29.8 mV for MSN-A-Bud). After coating MSN-A-Eu
shows negative charge of -20.9 mV, as positively charged amino
groups are covered by Eudragit S100. Coated particles loadedwith
drug have zeta-potential of −19.2 ± 2.8 mV (MSN-A-Pre-Eu) and
−19.5 ± 3.5 mV (MSN-A-Bud-Eu) confirming successful coating
of negatively charged Eudragit onto positively charged particles.
Surface area and pore size distribution were analyzed by nitro-
gen (N2) adsorption–desorption isotherm measurements. Pris-
tine (MSN) and amino-modified particles (MSN-A) exhibit IU-
PAC type-IV isotherms according to N2 adsorption–desorption
analysis, affirming the mesoporous nature of the prepared MSN
(Figure 2a). A steep capillary condensation step can be ob-
served from these two samples between relative pressure (P/Po)
of 0.2 and 0.4, indicating MSN and MSN-A have unchanged
pore structure after amino modification. Pristine particles have
a (Brunauer–Emmett–Teller) BET surface area of 550 m2 g−1
(Table 2). MSN-A shows reduced BET surface area (489 m2 g−1)
because of binding of amino silane. After drug loading, the sur-
face area of particles further decreases to 231 m2 g−1 (MSN-A-
Pre) and 345m2 g−1 (MSN-A-Bud), as pore volume is occupied by
prednisolone and budesonide respectively. Eudragit S100 coated
particles (MSN-A-Eu) shows even lower surface area of 241 m2
g−1 because of the coverage of polymer chain. Surface area of
MSN-A-Pre-Eu and MSN-A-Bud-Eu further drop to 226 and 220
m2 g−1. The N2 adsorption-desorption isotherm measurements
confirmed that mesoporous pore structure of MSN-A-Eu was
blocked, indicating the successful coating. Reduced pore size of
MSN-A (2.0 nm) compared to MSN (2.2 nm) comes from intro-
duced amino silane (Figure 2). Similarly, pore volume of parti-
cles reduced from 1.20 to 0.99 cm3 g−1 after amino modification.
MSN-A-Pre,MSN-A-Bud, andMSN-A-Eu showed pore volume of
0.48, 0.54, and 0.51 cm3 g−1. Coated particles with drug showed
lowest pore volume of 0.16 cm3 g−1 (MSN-A-Pre-Eu) and 0.19
cm3 g−1 (MSN-A-Bud-Eu).
Loading percentage (w/w) of prednisolone is 16.8% and 29.2%
for particles with (MSN-A-Pre-Eu) and without (MSN-A-Pre)
coating, respectively, with loading efficiency of 95.2% and 97.3%.
Adv. Therap. 2020, 2000165 © 2020 Wiley-VCH GmbH2000165 (3 of 11)
www.advancedsciencenews.com www.advtherap.com
Figure 2. a) N2 adsorption/desorption isotherms and b) pore size distributions (Barrett−Joyner−Halenda Adsorption dV/dD Pore Volume) of MSN,
MSN-A, andMSN-A loadedwith budesonide/prednisolone (MSN-A-Bud/MSN-A-Pre), particles with Eudragit S100 coating (MSN-A-Eu), and drug loaded
particles with Eudragit S100 coating (MSN-A-Bud-Eu/MSN-A-Pre-Eu).
Figure 3. Weight loss profile of MSN, MSN-A, and MSN-A loaded with
budesonide/prednisolone (MSN-A-Bud/MSN-A-Pre) and drug loaded
nanoparticles with Eudragit S100 coating (MSN-A-Bud-Eu/MSN-A-Pre-
Eu) determined by TGA from 100 to 900 °C.
For budesonide, loading percentage (w/w) was 9.0% for MSN-A-
Bud-Eu and 19.1% forMSA-A-Budwith 82.0% and 95.5% loading
efficiency. Loading of prednisolone and budesonide were quanti-
fied via UV visible for prednisolone and using HPLC for budes-
onide. Drug loading was further confirmed with thermogravi-
metric analysis (TGA) (Figure 3). Weight losses were determined
by computed as functions of temperature in comparison to re-
spective control. Weight loss was calculated from 120 oC to ex-
clude weight loss from moisture. MSN-A appears 15.4% weight
loss, which is 7.7% higher than that of pristine particles, confirm-
ing success of amino modification. Further weight loss observed
inMSN-A-Pre andMSN-A-Bud comes from loaded prednisolone
and budesonide. MSN-A-Pre-Eu and MSN-A-Bud-Eu appear to
have the most weight loss because of Eudragit coating.
Wide angle X-ray diffraction (WXRD) was performed to con-
firm the nature of encapsulated prednisolone and budesonide
within mesopores of MSN. The WXRD spectrum between a 2𝜃
ranges of 10o to 40o were obtained for MSN with and without
loading (Figure 4). Pure prednisolone and budesonide showmul-
tiple sharp diffractions peaks from 10o to 30o, corresponding to
lattice orientations from crystalline molecule. The amorphous
nature of MSN-A and Eudragit S100 is evidenced by the absence
of sharp peaks from 10o to 40o.[30] The diffraction peaks cor-
responding to free drugs can still be observed in drug-loaded
MSN (i.e., MSN-A-Pre and MSN-A-Bud), indicating limited crys-
talline state of loaded drug. Interestingly, for MSN-A-Bud, al-
though most of the diffraction peaks corresponding to budes-
onide are not as sharp as free budesonide, a very sharp peak
is observed at 12o. However, for the drug loaded nanoparticles
with Eudragit S100 coating, no diffraction peaks originating from
crystalline drug was observed, suggesting that loaded drug is en-
trapped withinMSN-A and polymer nanocomposites in an amor-
phous form.[30]
2.2. In Vitro Release of Fabricated pH-Responsive Nanoparticles
The pH-responsive in vitro release was studied by suspending the
drug-loaded particles in pH 1.9 aqueous buffer solutions (univer-
sal buffer according to USP). At 2 and 5 h time points, the pH
of the buffer was adjusted to 5.5 and 7.4, respectively, to mimic
the progressive pH environments of the GIT. Free prednisolone
shows burst release of around 86% in the first 2 h at pH 1.9. Sim-
ilar release profile was observed for MSN-A-Pre with 76% release
(Figure 5a) in the first 2 h. However, MSN-A-Pre-Eu showed only
18% drug release in the first 2 h (pH 1.9) and additional 10% re-
leased between 2 and 5 h (pH 5.5), followed by up to 78% release
over 24 h after the pH was adjusted to 7.4. For budesonide, free
drug was released up to 56% in the first 2 h, followed by 71%
release in 24 h. Compared to prednisolone, budesonide shows
limited dissolution, which is because of its poor aqueous solu-
bility. The release of MSN-A-Bud followed similar trend to free
budesonide with around 80% budesonide release in first 5 h (Fig-
ure 5b). The pH-responsive release was also observed fromMSN-
A-Bud-Euwith only 12% release at pH 1.9 and another 7% release
at pH 5.5. Approximately 60% loaded budesonide was released
only after pH was adjusted to 7.4 consistent with MSN-A-Pre-Eu.
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Figure 4. Wide angle X-ray diffractograms (WXRD) patterns of a) free drug and drug-loaded silica nanoparticles, b) free polymer (Eudragit S100) and
coated and drug-loaded nanoparticles.
Figure 5. a) Cumulative release profile of prednisolone and b) budesonide from free drug, particles with and without coating exposed in universal buffers
at 37 °C. Release was started at pH 1.9 for the first 2 h. Then pH was adjusted to 5.5 for 3 h. At last, pH was adjusted to 7.4 till end of release. Data
represent mean ± SD, (n = 3).
Therefore, for both drugs, loading and Eudragit S100 coating pro-
vides protection from acidic pH, leading to potentially promising
pH-responsive drug delivery for IBD.[14]
2.3. In Vivo Efficacy Against DSS-Induced Colitis
The therapeutic efficacy of budesonide encapsulated in Eudragit
S100 coated silica nanoparticles in the DSS-induced colitismodel
was investigated because of the known anti-inflammatory proper-
ties of budesonide in this model.[31] DSS directly damages the in-
testinal lining allowing luminal content to come in direct contact
with the epithelium. These results in immune activation in the
intestinal epithelium, immune cell infiltration, and subsequent
epithelial inflammation.[28] These made DSS model one of the
most widely used murine models due to its simplicity, rapidity,
controllability, reproducibility, and resemblance to human ulcer-
ative colitis.[32]
We scored the animals for disease severity in terms of diarrhea
score and rectal bleeding, which were cumulatively represented
as DAI score in Figure 6a (Histology scoring sheet DSS colitis,
Supporting Information). The result showed that all treatment
groups improved DAI score compared to DSS colitis group, espe-
cially MSN-A-Bud and MSN-A-Bud-Eu (Figure 6a). DSS caused
significant body weight loss, increased colon weight, decreased
length, and increased weight–length ratio (Figure 6b–e). How-
ever, no significant improvement of colon weight or length was
observed in the treatment groups. We also measured histological
colitis by scoring the hematoxylin and eosin (H&E)-stained
sections. As expected, DSS colitis group had highest histological
score confirming inflammation. Representative images from
each group and blind assessment of histological colitis, are
shown in Figure 7. In the proximal colon, preservation of epithe-
lial cells can be observed in all treatment groups, including free
budesonide group, compared to DSS colitis group (Figure 7).
Interestingly, MSN-Bud showed reduced histological colitis score
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Figure 6. Therapeutic efficacy of budesonide dosages on IBD model of DSS-induced colitis in mice. For treatment groups, 0.2 mg kg-1 budesonide and
equivalent dose loaded particles were given via oral gavage in PBS daily from day 7 to day 11. Colon tissues were collected andmeasured after sacrifice on
day 12. PBS or particles without loading in PBS were given to the control group via oral gavage at same time point. Data were collected from 4 mice per
group in two independent experiments. a) DAI (disease activity index: diarrhea + rectal bleeding): *p < 0.05, **p < 0.01, and ****p < 0.0001, compared
to DSS colitis group; b) body weight normalized as percentage of initial body weight; c) colon weight, d) length, and e) colon weight/length ratio. **p
< 0.01, ***p < 0.001, and ****p < 0.0001, compared to healthy control. DAI and body weight were analyzed by two-way ANOVA. Colon weight, length,
and weight/length ratio were analyzed by one-way ANOVA (Dunnett’s multiple comparisons test). Data are presented as mean ± SD (n = 8).
similar to MSN-A-Bud-Eu. It is possible that because of the pH
and composition differences between healthy and inflammatory
condition, the release of budesonide from the nanoparticles
was slower than that observed in vitro. This may also be the
reason that encapsulated budesonide did not show superior
therapeutic effect in the proximal colon compared to free drug.
Preservation of goblet cells and crypt structures can be observed
in MSN-Bud and MSN-A-Bud-Eu groups (Figure 8). Similarly,
free budesonide also showed improvement in histological colitis
in the distal colon. The results of distal colon indicate higher de-
livery efficiency of nanoparticles to the distal colon compared to
proximal colon. However, both nanoparticle groups loaded with
budesonide (MSN-Bud, MSN-A-Bud-Eu) showed significantly
reduced histological damage compared to DSS colitis group
and free budesonide (Figures 7 and 8). This can be a result of
incomplete dissociation of coated Eudragit S100 from decreased
pH values from inflammation in the intestinal tract,[33] and pos-
sible variation in colonic pH between human and mice, which
will need to be further investigated via pharmacokinetic studies.
Pharmacokinetic study is another potential way to differentiate
between different formulations and pure drug however due to
very low dose of Budesonide (0.2 mg kg−1) used in the study it
is very difficult to perform PK in mice as seen with many recent
studies using budesonide for the treatment of IBD.[13d,20c,21b,22c,34]
Therefore, in order to assess the ability of coated particles to
deliver budesonide more effectively, we decided to perform
qRT PCR of the colonic tissues in order to prove local delivery
and to study the expression of pro-inflammatory cytokines with
different treatment groups. Corroborating previous studies,
we observed an elevation in the levels of pro-inflammatory cy-
tokines including Il-1𝛽, Il-17, and Tnf-𝛼 (Figure 9).[35] Although
we did not observe any changes in the gene expression with free
budesonide, oral delivery using MSN-loaded budesonide and
Eudragit coated nanoparticles (MSN-A-Bud-Eu) enhanced the
anti-inflammatory activities of budesonide through reduction of
Il-1𝛽 (p < 0.05 and p < 0.01, respectively) and Il-17 (p < 0.01)
in the proximal site (Figure 9a,b). These can be supported by a
study fromDjaldetti and Bessler,[35h] who showed budesonide re-
duces production of IL-1𝛽 in the peripheral blood mononuclear
cells (PBMCs). We also observed a trend of reduced Il-1𝛽 and
Il-17 in the distal site (Figure 9d,e); however, no changes were
found in the expression of Tnf-𝛼 (Figure S7, Supporting Infor-
mation). Immunoregulatory cytokines such as Il-10 have shown
to be elevated during intestinal inflammation, which decline
after successful treatment.[35e] Interestingly, Eudragit-coated
nanoparticle with budesonide significantly reduced the Il-10
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Figure 7. Therapeutic efficacy of free and MSN formulated budesonide on IBD model of DSS-induced colitis on mice. Representative histology images
of H&E stained proximal colon sections from a) healthy control, b) DSS colitis, c) budesonide, d) MSN-A-Bud, e) MSN-A-Bud-Eu, and f) colitis score.
Histological colitis was assessed based on inflammation severity (IS), infiltration extent (IE), epithelial damage (ED), and percentage involvement of
epithelial damage (PD) (crypt abscessed, crypt loss, or ulceration). Data was analyzed by one-way ANOVA. *p < 0.05 and **p < 0.01, compared to DSS
colitis group. (one-way ANOVA followed by Dunnett’s multiple comparisons test). Data are presented as means ± SD (n = 8). Scale bars = 100 µm. Red
arrows indicate crypt loss and abscesses, blue arrows represent goblet cell damage, and green arrows represent neutrophil infiltration.
expression compared to DSS group, suggesting that there was
an overall reduction in inflammation in the intestine (Fig-
ure 9c,f). Djaldetti and Bessler have shown that budesonide
also reduced the production of IL-10 in the LPS-stimulated
PBMCs.[35h] Gene transfer[35a] or administration of IL-10[36] was
also shown to suppress experimental colitis, whereas deficiency
of IL-10 led to the development of colitis,[35b] demonstrating a
protective role of this cytokine to maintain intestinal homeosta-
sis. IL-10 was found to down-regulate expression of IL-1𝛽 in the
monocytes from colitis patients,[35d] which could be correlated
with the reduced expression of Il-1𝛽 in our experiment. More-
over, IL-10 was also shown to suppress Th17 immune responses
and reduce expression of pro-inflammatory cytokine IL-17.[35g]
As immune cells express IL-10 receptors, these indicate that
increased expression of IL-10 may produce an anti-inflammatory
environment in the colon by educating the infiltrated immune
cells. It has also been found that controlling an autoregula-
tive negative feedback mechanism, IL-10 can reduce its own
synthesis in monocytes.[35c] Besides, budesonide also reduced
immune cell infiltration in the inflamed colon (Figures 7 and 8).
Therefore, it is possible that reduced inflammatory state created
by budesonide also impacted on the observed level of Il-10 ex-
pression with nanoparticles treated colon. It is important to note
that when compared to budesonide only coated particles, (MSN-
A-Bud-Eu) reduced Il-10 expression in the distal colon further
attesting improved colonic delivery with coated particles. Overall,
these results demonstrated that encapsulation of budesonide
increased its therapeutic efficiency, and pH-responsive Eudragit
coating further enhanced the activity with less body weight loss,
less DAI and histological colitis scores, and decreased expres-
sion of pro-inflammatory cytokines in the DSS-treated animals.
These data therefore supported the effectiveness of budesonide
nanoformulation in ulcerative colitis. The limited recovery from
free budesonide could be because the severity of inflammation
was beyond efficacy of selected dose of budesonide. The observed
beneficial effects of encapsulated budesonide could be the result
of site-specific release of budesonide at the colonic site.
3. Conclusion
In this study, a colon targeting oral drug delivery system based
on mesoporous silica nanoparticles and Eudragit S100 was de-
veloped and optimized. Prepared silica nanoparticles≈150 nm in
size have well-defined spherical morphology and ordered meso-
porous structure. The encapsulation of drug and pH-responsive
polymer coating were achieved with a one-step rotary evaporation
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Figure 8. Therapeutic efficacy of free and MSN-formulated budesonide on IBD model of DSS-induced colitis on mice. Representative histology images
of H&E stained distal colon sections from a) healthy control, b) DSS colitis, c) budesonide, d) MSN-A-Bud, e) MSN-A-Bud-Eu, and f) colitis score.
Histological colitis was assessed based on IS, IE, ED, and PD. Data was analyzed by one-way ANOVA. *p < 0.05 and ***p < 0.001, compared to DSS
colitis group (one-way ANOVA followed by Dunnett’s multiple comparisons test). Data are presented as means ± SD (n = 8). Scale bars = 100 µm. Red
arrows indicate crypt loss and abscesses, blue arrows represent goblet cell damage, and green arrows represent neutrophil infiltration.
method. Corticosteroid drugs prednisolone (16.8% w/w) and
budesonide (9.0% w/w) were successfully encapsulated and
coated with Eudragit S100 onto synthesized particles. The poly-
mer coating with Eudragit S100 protected the loaded drugs
against the acidic condition of GIT before reaching colonic
site, and prevented premature release of both prednisolone and
budesonide. The therapeutic effect of budesonide was also tested
using a murine model of DSS-induced colitis. Encapsulation
of budesonide within MSN significantly reduced inflammation
compared to free drug via significant improvement in DAI and
histological lesion score, especially in the distal colon. Although
we did not find significant difference between coated and un-
coated particles in improving histology, coated nanoparticles ef-
fectively alleviated the DSS-induced upregulation of cytokines Il-
1𝛽, Il-10, and Il-17 compared to uncoated particles in the prox-
imal colon and Il-10 in the distal colon. Overall, the design of
pH-responsive mesoporous silica nanoparticles is promising as
a new cost-efficient oral delivery system for better IBD treatment.
Our future work will focus on assessing in vivo pharmacokinet-
ics of the released drug and delineating the role of particle accu-
mulation on improvement of disease pathology with and without
pH-responsive coating.
4. Experimental Section
Materials: 99% Tetraethylorthosilicate (TEOS), 99% hexade-
cyltrimethylammonium bromide (CTAB), 99% (3-aminopropyl) tri-
ethoxysilane (APTES), and 99% prednisolone were purchased from
Sigma-Aldrich, St Louis, MO, USA. Ethanol, methanol, chloroform, and
32% hydrochloric acid was purchased from Merck KGaA, Darmstadt,
Germany. Phosphoric acid (H3PO4), acetic acid (CH3COOH), and
sodium hydroxide were purchased from Chem-Supply, Gillman, SA, Aus-
tralia. Budesonide was purchased from BioNet, Camelford, UK. Dextran
sodium sulfate (MW 36–50 kDa) was purchased from MP Biochemicals,
Illkirch, France. Eudragit S100 was a generous gift from Evonik, Germany.
Phosphate-buffered saline tablets were purchased from MP Biomedicals,
Santa Ana, CA, USA. ISOLATE II RNA Mini Kit (BIOLINE, Australia), and
SensiFAST cDNA synthesis kit (BIOLINE, Australia) were used as directed
by the manufacturer.
Synthesis of Mesoporous Silica Nanoparticles: Mesoporous silica
nanoparticles were synthesized according to a previously reportedmethod
with specific modification.[37] Briefly, 1.0 g of CTAB was added in 480 mL
of deionized (DI) water at ambient temperature, followed by addition of
3.5 mL of 2 m of NaOH and heated to 80 oC. The mixture was stirred
for 2 h after adding 6.7 mL of TEOS. The resultant suspension was vac-
uum filtered and washed by DI water and ethanol. Washed particles were
dried overnight at 60 oC and kept for further experiment. Surfactant was
removed by solvent extraction, according to the reported protocol with
slight modifications.[38] For this, 0.6 g of particles were dispersed in 64mL
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Figure 9. Gene expression of Il-1𝛽, Il-17 and Il-10 in the proximal (a–c) and distal (d–f) colon were determined by qRT-PCR. Tata box was used as
a housekeeping gene. Expression level was normalized to healthy control. Data are presented as mean ± SEM (n = 8), § p < 0.05 compared with
budesonide group, * p < 0.05; ** p < 0.01 compared with DSS group and # p < 0.05; ## p < 0.01 compared with control group (one-way ANOVA
followed by Dunnett’s multiple comparisons test).
of ethanol and 4.0 mL of hydrochloric acid (32%) and stirred at 60 oC for
36 h. Particles were retrieved by centrifugation at 20 000 g for 10 min and
washed with DI water and ethanol. Washed particles were dried overnight
and denoted as MSN for further studies.
Amino Functionalization of Mesoporous Silica Nanoparticles: Amino-
functionalized MSNs were prepared according to previously reported
method with slight changes.[39] Functionalization was processed before
surfactant removal to avoid blockage of pore entrance. Briefly, 0.8 g of
MSNswithout surfactant removal was dispersed in 50mL ofmethanol. Af-
ter adding 3.0 mL of APTES, the mixture was stirred at room temperature
overnight. Modified particles were retrieved and washed by centrifugation
and dried overnight. Solvent extraction was carried out after functionaliza-
tion as described above. Prepared particles were noted as MSN-A.
Eudragit S100 Coating and Drug Loading: Eudragit S100 coated MSN-
A loaded with prednisolone was prepared with rotary evaporationmethod.
30 mg of prednisolone was dissolved in 1 mL of methanol. 70 mg of MSN-
A was dispersed in another 1 mL of methanol and mixed with 1 mL of
methanol with prednisolone. Next, 70 mg of Eudragit S100 was dissolved
in another 2mL ofmethanol and added into the suspension ofMSN-A and
prednisolone. Mixture was sonicated in water bath for 30 min. Methanol
was then evaporated with a rotary evaporator at 40 oC. Collected particles
were noted as MSN-A-Pre-Eu. Budesonide was loaded with same method
with different ratio (20 mg budesonide/80 mg MSN-A/80 mg Eudragit
S100) and noted as MSN-A-Bud-Eu. Please note that the Eudragit S100
coated particles without loading are denoted asMSN-A-Eu throughout the
manuscript.
Characterization: TEM images were obtained with a Hitachi 7700 mi-
croscope operated at 80 kV. Particle size and zeta-potential of the prepared
MSNs were measured with DLS setup (Malvern, Nano-ZS, ATA Scientific,
Taren Point, Australia). Surface area and pore volume were measured with
nitrogen absorption (N2-BET), (Tristar 3020, Micromeritics-II, Norcross,
GA, USA). WXRD was recorded on a Rigaku Miniflex X-ray diffractometer
with Cu radiation (k = 1.54 Å). TGA was performed with a heating rate
of 10 °C min-1 under ambient air (Mettler Toledo, TGA/DSC 2, Columbus,
OH, USA). Drug content was quantified according to reportedmethod.[40]
Prednisolone was analyzed with Agilent Cary 60 UV–visible spectropho-
tometer at a wavelength of 250 nm. Budesonide was analyzed using HPLC
(Nexera-I LC-2040 3D, Shimadzu, Japan) with an UV/visible detector at a
wavelength of 254 nm and Luna C18 column (150 × 4.6 mm, 5 µm Phe-
nomenex, USA), eluted with 70% v/v methanol in water at a flow rate
of 1.5 mL min−1. Loaded drug was quantified after extraction from par-
ticles with methanol. Loading percentage and efficiency of prednisolone
and budesonide were calculated with the following equations:
Loading percentage (%) =
Amount of drug loaded
Total amount of MSNs and loaded drug
×100% (1)
Loading efficiency (%) =
Amount of drug loaded
Total amount of drug initially used for loading
×100% (2)
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In Vitro pH-Responsive Drug Release: The pH-responsive drug re-
lease properties of the Eudragit S100 coated silica nanoparticles loaded
with prednisolone and budesonide were elucidated using the “universal
buffer,” according to the United States Pharmacopeia (USP).[40a] Typically,
1 mg of drug and equivalent dose of drug-loaded particles were dispersed
in 100mL of universal buffer. Universal buffer was prepared bymixing 0.05
m of acetic acid and 0.05 m of phosphate buffer 1:1 by volume (pH 1.9).
The pH of release media was adjusted to 5.5 and 7.4 with 8 m of NaOH
at 2- and 5-h time points to mimic the progressive pH change of GIT. At
specific time intervals, 2 mL of release media was collected and replaced
with fresh release media. The collected release media was centrifuged at
20 000 g for 10 min to separate possible suspended nanoparticles, and the
amount of drug in supernatant was quantified.
DSS-Induced Colitis Model: All animal research and experiment proto-
cols were approved by the Animal Ethics Committee of the University of
Queensland and conducted according to National Health andMedical Re-
search Council guidelines. AEC Approval Number: PHARM/TRI/251/18.
The 6-week-old male C57BL/6J mice were obtained from Animal Re-
sources Centre (ARC). Formulated drinking water with 1.5% DSS water
was provided ad libitum from day 0 for 7 days. Normal drinking water
was provided from day 7. The body weights of mice were monitored and
recorded. Each mouse was examined daily to record the disease activity
index (DAI). DAI is defined as the diarrhea score plus the rectal bleeding
score. Details of scoring are listed below. For diarrhea and rectal bleeding
scoring, 0 = normal/equivocal symptoms, 1 = mild symptoms, and 3 =
severe symptoms. For weight loss scoring, 0 ≤ 5% weight loss, 1 = 5–14%
weight loss, 2= 15–19%weight loss, and 3≥ 20%weight loss (Supporting
Information).[41]
For therapeutic efficacy experiment, 6-week-old male C57BL/6J mice
were divided into seven groups (n = 8 per group). 0.2 mg kg−1 free budes-
onide and budesonide-encapsulated nanoparticles with equivalent dose
were dispersed in PBS and given to the corresponding group via oral gav-
age daily from day 7 to day 11. Body weight and DAI were recorded daily.
Animals were sacrificed on day 12. Colonic tissues were collected, cut lon-
gitudinally, with fecal material removed gently with a pipette tip and mea-
sured for weight and length. For histological assessment of DSS colitis,
samples were fixed in formalin overnight. Fixed tissues were then dehy-
drated in ethanol overnight and embedded in paraffin. 5 µm sections of
rolled colon tissue were cut and fixed on slides, stained with H&E. Stained
slides were scanned and scored in blinded fashion, according to validated
scoring system by inflammation severity, infiltration extent, epithelial dam-
age, and percentage involvement of epithelial damage (crypt abscessed,
crypt loss, or ulceration), using a well-developed scoring system.[42] Quan-
titative real time polymerase chain reaction (qRT-PCR) of colon tissue was
processed with ISOLATE II RNA Mini Kit (Bioline), according to the man-
ufacturer’s instructions.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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